Premium
Is M cl‐1 L the new anti‐apoptotic effector of B ‐ RAFV 600E in melanoma?
Author(s) -
Bergamaschi Daniele
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12312
Subject(s) - melanoma , apoptosis , in vivo , effector , cancer research , chemistry , microbiology and biotechnology , biology , genetics
A recent report has unveiled a novel mechanism by which oncogenic BRAF signalling might trigger apoptotic resistance in melanoma by selectively affecting the expression of B cl‐2 family member M cl‐1 L ( Exp Dermatol 2013: 22 : 767). Correlation of M cl‐1 splice variants and B ‐ RAF mutational status was determined in a panel of melanoma cell lines. In vivo validation of this mechanism, which is supported by recent literature, might provide novel therapeutic approaches such as the use of targeted M cl‐1 inhibitors to improve outcome in melanoma.